Kevin Afra

Clinical Assistant Professor

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Pharmacy Pharmacy professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kevin Afra is a Clinical Assistant Professor at the University of British Columbia, Canada. His research focuses on antimicrobial susceptibility trends, antibiotic prescribing patterns, and clinical outcomes related to infectious diseases. He has published extensively on topics such as the evaluation of intravenous antibiotics and guidelines for managing patients post-vaccination-related adverse events.

Articles (10)

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Ines Pauwels

University of Antwerp

BELGIUM

View details

Fiona Doukas

Infectious Diseases and Antimicrobial Stewardship Pharmacy Advanced Training Mentor

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kevin Afra

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Current Antimicrobial Susceptibility Trends and Clinical Outcomes of Typhoidal Salmonella in a Large Health Authority in British Columbia, Canada

Evaluation of intravenous amoxicillin-clavulanate use in two Canadian hospitals

Cardiac and vascular serious adverse events following tixagevimab-cilgavimab.

Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination.

Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries.

The 2018 Global Point Prevalence Survey of antimicrobial consumption and resistance in 47 Canadian hospitals: a cross-sectional survey

Tocilizumab for hospitalized patients with COVID-19.

Oral beta-lactam step down in bacteremic E. coli urinary tract infections.

The 2017 global point prevalence survey of antimicrobial consumption and resistance in Canadian hospitals.

Developing a Tool for Prospective Assessment of Treatment Appropriateness in Urinary Tract Infections.

Collaborators (2)

Ines Pauwels

Fiona Doukas

Make your next move.